Epcoritamab Gives Deep Response in Richter’s Transformation
October 11, 2024
Epcoritamab, a bispecific antibody, led to a 50% overall and 35% complete response rate in all Richter’s transformation patients.
Epcoritamab, a bispecific antibody, led to a 50% overall and 35% complete response rate in all Richter’s transformation patients.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.
While the incidence of Richter’s transformation has not changed dramatically with the introduction of targeted therapies, those who received CLL / SLL treatment in the targeted therapy era appear to have a lower risk of Richter’s transformation.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This was a very complex basic science presentation from iwCLL 2023 by Erin Parry, MD. Ph.D. of Dana Farber Cancer Institute in Boston, MA on the evolution of CLL (chronic lymphocytic leukemia) to Richter’s transformation (RT),
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).